All done here! Check out our other subjects!
Contents
Abstract
- Chronic diseases such as rheumatoid arthritis have an effect on the different components of blood. These diseases can eventually result in anaemia of chronic disease.
- Chronic diseases cause the production of cytokines (signalling proteins released during inflammation). Cytokines stimulate hepcidin, a hormone made in the liver that controls iron. Hepcidin blocks iron absorption in the gut and traps iron inside macrophages. The iron is still in the body but cannot be used. This is called a functional iron deficiency, and it leads to anaemia.
- Cytokines also inhibit the production of erythropoietin (EPO), a hormone made by the kidney that stimulates red cell production. This reduces erythropoiesis (the making of red blood cells).
- Macrophage activity in chronic disease is increased which means red blood cells are broken down more quickly, so there are fewer red cells in circulation resulting in anaemia.
- Chronic diseases that cause anaemia of chronic disease include: chronic kidney disease, rheumatoid arthritis, chronic liver disease
Core
Haematology is often used as a method of diagnosis for diseases of many different types, normally through analysing blood from the patient. An abnormal blood result may be caused by a systemic disease (a disease that affects the whole body) rather than by a primary blood disorder (a disease that starts in the blood or bone marrow). Abnormal results come about when one or more of the following is compromised: the production of blood cells, their time in circulation or the removal mechanisms for the blood cells.
The causes of the abnormal results are often multifactorial (there are many contributing causes), because systemic diseases influence the blood in many ways. These influences may come from the disease itself, its complications or its treatment.
Anaemia of chronic disease is also known as anaemia of inflammation. It is a very common condition (the commonest anaemia in hospital patients). It is associated with chronic inflammatory conditions (e.g. rheumatoid arthritis and systemic lupus erythematosus, an autoimmune disease that can affect many organs), chronic infections (e.g. tuberculosis) and malignancy (cancer).
In any inflammatory response, cytokines (e.g. interleukin-6, IL-6) are released from immune cells. This release of cytokines has 3 key effects:
- Firstly, cytokines stimulate the production of hepcidin in the liver. Hepcidin causes ferroportin (the protein that lets iron out of cells and into the blood) to be broken down (see the article on iron metabolism). This has two effects. It decreases the amount of iron absorbed in the gut, and it reduces the release of iron stored in macrophages as ferritin (the iron storage protein). Together these lead to a functional iron deficiency. The deficiency is functional in nature because the iron stores in the body are normal or even raised, but the iron is inaccessible.
- Secondly, cytokines inhibit erythropoietin (EPO) production by the kidney. This issue is compounded by the fact that cytokines reduce the bone marrow’s responsiveness to the already limited EPO. Overall, erythropoiesis (production of red blood cells) is inhibited.
- Finally, the inflammation from the disease increases the activity of the macrophages in the reticuloendothelial (RE) system (the macrophages in the spleen, liver and bone marrow that remove old cells), shortening the lives of the red blood cells (erythrocytes). These factors together cause the anaemia.
The MCV (mean cell volume, the average size of the red cells) is usually normal, so the anaemia is normocytic (normal-sized red cells) and normochromic (normal colour). It becomes microcytic (smaller than normal red cells) if iron deficiency also develops.
The severity of kidney failure in chronic kidney disease (CKD) is usually proportional to the severity of anaemia experienced. Renal function and dysfunction can affect erythropoiesis through several mechanisms:
- Clearance of Hepcidin - as less hepcidin is cleared by the failing kidneys, there is a greater concentration in the blood causing the unwanted effects of hepcidin as stated above.
- Erythropoietin Production - damage to the kidneys decreases the amount of erythropoietin produced. With less EPO produced there is less stimulation of the bone marrow, so reduced proliferation of the erythrocytes.
- Raised Cytokines - chronic inflammation in the kidneys increases cytokine release from the immune cells. As stated above, this decreases the bone marrow’s response to EPO.
- Uraemia - if the kidneys are failing they are ineffective at filtering and removing urea (a waste product) from the blood, leading to uraemia. This causes inflammation of the blood vessels and so raises the number of cytokines. Uraemia also impairs platelet function, so platelets stick together and to the vessel wall poorly, which increases the risk of bleeding. Finally, uraemia directly reduces the erythrocyte lifespan.
- Dialysis (treatment that does some of the work of failed kidneys) - this can cause damage to the erythrocytes as they pass through the dialysis machine. Note there is also the possibility of bleeding with haemodialysis (dialysis that filters the blood through a machine).
The anaemia is typically normocytic (normal-sized red cells) and normochromic (normal colour) on investigation, and becomes microcytic (small red cells) if iron deficiency is also present. It is hypoproliferative: the bone marrow makes too few new red cells, so the reticulocyte count (reticulocytes are immature red blood cells) is low, not high. Ferritin (the iron storage protein) can be normal or raised because inflammation increases it, so NICE advises against using ferritin alone to assess iron deficiency in CKD. Note that CRP (C-reactive protein, a blood marker of inflammation) is often raised due to inflammation. The anaemia is treated alongside the CKD, not after it. Check the haematinics (substances needed to make red cells: B12, folate and iron) and optimise iron status before, or at the same time as, starting an erythropoiesis-stimulating agent (ESA, a drug that works like EPO). ESAs are offered to people who are likely to benefit, usually aiming for a haemoglobin of 100 to 120 g/litre rather than a normal level. Note that iron often needs to be given IV, particularly in dialysis patients, as absorption of oral iron is reduced due to the action of hepcidin. Blood transfusion is not a routine final step. NICE advises avoiding transfusion if possible in people who may have a kidney transplant, and using it only when it is clinically indicated.
Abnormal blood results in a patient with CKD can be caused by a wide range of factors. Here are a few suggested causes to consider:
- Erythrocyte count:
- Anaemia (low):
- Diabetes can cause renal failure, which contributes to anaemia of chronic disease.
- Other haematinic causes include iron deficiency.
- Polycythaemia (high red cell count):
- Erythropoietin-secreting renal tumours can increase haematopoiesis (the making of blood cells).
- Anaemia (low):
- White cell count:
- Neutropenia (low neutrophil count):
- The patient could be on immunosuppression medication (drugs that dampen the immune system) after a kidney transplant to prevent rejection.
- Bone marrow inflammation can reduce the production of white cells.
- Neutrophilia (high neutrophil count):
- Inflammation leads to increased white cell activation.
- Steroids, which can be given to reduce immune causes of kidney failure, can themselves raise the neutrophil count.
- Any infection in the kidney could raise the white cell count.
- Neutropenia (low neutrophil count):
- Platelet count:
- Thrombocytopenia (low platelet count):
- If present, uraemia is directly toxic to megakaryocytes which produce platelets, inhibiting production.
- Some drugs used to treat renal failure can cause a low platelet count.
- Thrombocytosis (high platelet count):
- If the patient is iron deficient this can lead to an increased count.
- Thrombocytopenia (low platelet count):

Image - A hand with rheumatoid arthritis
Creative commons source by James Heilman, MD [CC BY-SA 3.0 (https://creativecommons.org/licenses/by-sa/3.0)]
Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory condition which primarily targets the small joints in the hand causing pain and joint stiffness. Firm swellings known as rheumatoid nodules can develop under the skin around the affected joints in the later stages of disease. These nodules are made up of fibrous tissue surrounding a central area of fibrinoid necrosis. Fibrinoid necrosis is a form of tissue death. In a typical nodule it is surrounded by palisading epithelioid macrophages (macrophages lined up around the dead tissue).
RA is treated with disease-modifying anti-rheumatic drugs (DMARDs), such as methotrexate (a drug that dampens the immune system). NICE advises starting a DMARD as soon as possible, ideally within 3 months of the start of persistent symptoms, to control inflammation and slow disease progression. Corticosteroids can be given for a short time while a new DMARD takes effect. Non-steroidal anti-inflammatory drugs (NSAIDs, such as ibuprofen) can be considered when pain or stiffness is not controlled.
There is a correlation between the severity of the rheumatoid arthritis and the severity of the anaemia of chronic disease resulting from the inflammation.
Abnormal blood results in a patient with RA can be caused by a wide range of factors. Here are a few suggested causes to consider:
- Erythrocyte count:
- Anaemia
- Anaemia of chronic disease.
- Long term NSAID use can cause peptic ulcers. This can cause blood loss leading to iron deficiency and anaemia.
- A haematinic deficiency (a lack of vitamin B12, folate or iron) is always a possibility, so consider it when other causes have been excluded.
- Methotrexate compromises the folate pathway: it inhibits the enzyme dihydrofolate reductase, which is essential for making purines and pyrimidines (building blocks of DNA). Patients on methotrexate are therefore given folic acid as a supplement to reduce side-effects, usually once a week on a different day from the methotrexate. There is no evidence that folic acid reduces the effect of methotrexate on blood counts, so patients on methotrexate need regular full blood counts.
- Anaemia
- White cell count:
- Neutrophilia
- Patients being treated with corticosteroids can have a high white cell count, because corticosteroids can cause a neutrophilia.
- Patients are susceptible to infections if on steroids. Any infection could raise the white cell count. The exception is a patient who is already neutropenic, for example because of methotrexate, which can reduce blood counts. Infection in a neutropenic patient can become neutropenic sepsis (sepsis with a very low neutrophil count), which needs immediate assessment in hospital.
- Neutrophilia
- Platelet count:
- Thrombocytopenia
- Immune dysfunction is often related to RA, if present this may increase the rate of platelet destruction.
- If present, splenomegaly (an enlarged spleen) will increase the rate of platelet destruction.
- Thrombocytosis
- Inflammation can cause a reactive thrombocytosis (a raised platelet count caused by another condition rather than a bone marrow disorder), because cytokines such as interleukin-6 stimulate thrombopoietin (the hormone that stimulates platelet production). Iron deficiency, for example from blood loss from a peptic ulcer caused by NSAIDs, can also raise the platelet count.
- Thrombocytopenia

Diagram - Felty's syndrome triad
SimpleMed original by Dr. Tom Bradley
Felty’s syndrome is a triad of rheumatoid arthritis, splenomegaly and neutropenia. Thrombocytopenia and anaemia are also associated with the syndrome. The neutropenia has more than one cause. White cells are destroyed faster by the reticuloendothelial system, and they are trapped (sequestered) in the spleen. The bone marrow also produces fewer neutrophils, for example because of suppression by large granular lymphocytes or antibodies against G-CSF (granulocyte colony-stimulating factor, the cytokine that stimulates neutrophil production). The immune processes in rheumatoid arthritis can also lead to the destruction of white cells in the peripheral circulation.
Chronic liver disease (cirrhosis) will lead to portal hypertension (raised pressure in the portal vein, which carries blood from the gut to the liver) as the scarring of the liver restricts blood flow through it. This causes a backup of blood into the portal system and therefore an increased pressure within. This portal hypertension causes a pooling of blood within the spleen and so leads to splenomegaly. The splenomegaly causes excess sequestration and removal of cells within the spleen, reducing the red and white cell count.
The portal hypertension can also cause oesophageal and gastric varices (swollen, enlarged veins). Varices occur at points where the portal system and systemic circulation meet. Due to the high pressure in the portal system, the pressure is relieved by shunting blood through small surface veins into the lower pressure systemic circulation. This increased blood flow through these small veins leads to them becoming enlarged and at risk of bursting and leading to bleeding which can be very severe. The bleeding is exacerbated by the deficiency of vitamin K dependent clotting factors II (prothrombin), VII, IX and X which accompanies liver disease. This is as all these factors are normally synthesised in the liver, but with cirrhosis, synthesis decreases. Levels of various other clotting proteins also fall. However, clotting is not simply impaired. Changes that favour bleeding and changes that favour clotting happen together, so haemostasis (the balance between bleeding and clotting) is rebalanced rather than lost. Patients with cirrhosis can therefore have clotting complications as well as bleeding, and a prolonged prothrombin time does not by itself show a high risk of bleeding. Blood loss in such a manner can lead to anaemia in patients with liver disease and can cause an iron deficiency.
Dysfunction of the endothelial cells (the cells lining blood vessels) is also associated with thrombocytopenia, because it contributes to platelet consumption.
Patients with advanced liver disease can develop a haemolytic anaemia (anaemia caused by red cells breaking down early) called spur cell anaemia. Changes in the lipids of the erythrocyte membrane lead to abnormally shaped erythrocytes called acanthocytes, which have irregularly spaced spikes. These rigid cells are more prone to damage during circulation and are destroyed early in the spleen, which contributes to the haemolytic anaemia. Zieve’s syndrome is a separate and rare cause of haemolytic anaemia. It is classically defined by haemolytic anaemia, hyperbilirubinaemia (a high bilirubin level, which causes jaundice) and transient hyperlipidaemia (raised blood lipids) after recent heavy alcohol use.
Thrombocytopenia is common in chronic liver disease as levels of thrombopoietin, synthesised mainly in the liver, are reduced. Thrombopoietin’s function is to stimulate the production of platelets by the megakaryocytes in the bone marrow. Due to splenomegaly, patients will also pool and destroy platelets in the spleen. (Some immune causes of liver disease also produce antibodies against platelets.) Finally, platelet function is also altered in liver disease, as part of complex changes in the clotting system, so a low platelet count is only one factor in the risk of bleeding.
Viral hepatitis (infection of the liver) can rarely be associated with bone marrow failure. This leads to aplastic anaemia, in which there is marked loss of haematopoietic (blood-forming) stem cells and the marrow is replaced with fat.
Alcohol is a key cause of liver cirrhosis and so is indirectly linked to all the effects above. However, alcohol can also affect the blood directly.
Alcohol in excess is directly toxic to the cells in the bone marrow, and so suppresses haematopoiesis causing macrocytic erythrocytes (larger than normal red cells) and thrombocytopenia (a low platelet count).
Acetaldehyde (a product of ethanol metabolism) can bind to proteins on erythrocyte membranes. In some patients this alters membrane antigens, meaning the erythrocytes may be recognised as foreign and an immune response mounted against them.
As a general rule, alcoholic patients have poor nutrition, so may be lacking in the haematinics (substances needed to make red cells: vitamin B12, iron and folate). Megaloblastic anaemia (anaemia with large, immature red cells) is common in hospital patients who drink heavily and is mainly due to folate deficiency. Iron deficiency causes a microcytic anaemia (small red cells) instead.
It is common for haematological changes (changes in the blood results) to appear post-surgery, particularly a minor thrombocytosis and neutrophilia. It is very important to compare these results with the patient’s pre-surgery results. This shows whether the changes are just due to the surgery or point to a systemic condition. Anaemias can occur due to blood loss during surgery or dilution of the blood by fluids given during the surgery.
- Erythrocyte count:
- Anaemia
- Blood loss during surgery.
- If a large amount of fluids are given during surgery, a dilutional anaemia may present.
- Polycythaemia
- Dehydration may lead to a relative increase in erythrocytes due to reduced plasma volume.
- Anaemia
- White cell count:
- Neutropenia
- Severe infection (sepsis) and some medications.
- Neutrophilia
- Infection post-surgery is common so the immune response is triggered to control the infection and so the white cell count is raised.
- Neutropenia
- Platelet count:
- Thrombocytopenia
- Medication, such as antibiotics or heparin (an anticoagulant, a drug that stops blood clotting). Heparin can cause heparin-induced thrombocytopenia (HIT), an immune reaction that lowers the platelet count and can be complicated by thrombosis (clot formation). If HIT is strongly suspected or confirmed, the heparin is stopped and an alternative anticoagulant is given.
- A complication of sepsis is a condition of excessive clotting known as disseminated intravascular coagulation (DIC) which uses up platelets.
- Thrombocytosis
- A raised platelet count (reactive thrombocytosis) is common after surgery. It is a reactive response to tissue injury and inflammation: cytokines such as interleukin-6 stimulate thrombopoietin, which increases platelet production.
- Thrombocytopenia
Chronic infections such as tuberculosis and hepatitis B can cause anaemia of chronic disease through long term inflammation of tissues (as explained above).
Other conditions of note include malaria as it causes a haemolytic anaemia. Malaria parasites (Plasmodium) enter the erythrocyte, multiply and are finally released when the erythrocyte ruptures.
As a general rule, most bacterial infections cause a neutrophilia to counter the infection, viral infections can cause lymphocytosis (a high lymphocyte count, especially seen in children) and parasitic infections caused by tissue-invasive helminths (worms) are related to eosinophilia (a high eosinophil count).
Infections can also cause a reactive thrombocytosis (a raised platelet count caused by inflammation rather than a bone marrow disorder). The rise is driven by inflammatory cytokines such as interleukin-6, which stimulate thrombopoietin and so platelet production.
If the infections are untreated then they can progress to sepsis. A raised neutrophil count is usual in infection, but in sepsis the neutrophil count can instead fall (neutropenia), and the platelet count can fall (thrombocytopenia) due to DIC. DIC is a pathological activation of coagulation. This causes formation of multiple widespread microthrombi. Formation of these microthrombi uses up both the clotting factors and platelets. It puts patients at severe risk of both strokes and other blockages of blood vessels (occlusive events) and of life-threatening haemorrhage. DIC is identified from a combination of tests: the platelet count, the prothrombin time (PT, reported as the international normalised ratio or INR), fibrinogen and D-dimer (a marker of clot breakdown). The activated partial thromboplastin time (APTT) can also be prolonged.
Non-haematological cancers can cause different haematological changes depending on their origin. For example, bowel cancer can cause bleeding which may develop into an iron deficiency anaemia.
The treatment of cancer using chemotherapy (anticancer drugs) can cause anaemia, neutropenia and thrombocytopenia as it targets rapidly dividing cells which includes the rapidly dividing progenitor cells (early cells that develop into mature blood cells) within the bone marrow. Damage to these progenitor cells will lead to overall decreased production of blood cells. Therefore, patients undergoing chemotherapy may need supportive blood product transfusions and are at an increased risk of a neutropenic sepsis.
Sometimes cancers involve the bone marrow, either because they start there or because they spread to it. Non-haematological cancers that spread to the bone marrow (bone marrow metastasis) can cause anaemia and thrombocytopenia, because the marrow is infiltrated and suppressed. See our article on when haematopoiesis goes wrong for more information on cancers that start in the bone marrow. Marrow involvement can produce a leucoerythroblastic blood film, which shows immature white cells (granulocyte precursors) and nucleated erythrocytes (red cells that still contain a nucleus). Note that this film pattern can also be found in septic or shocked patients and in severe megaloblastic anaemias.
Platelet counts can be high with cancers. This is often a reactive thrombocytosis (a raised platelet count caused by another condition rather than a bone marrow disorder). Malignancy, inflammation, iron deficiency and blood loss are all common causes. A high platelet count can be a concern in cancer because these patients are at an increased risk of venous thromboembolism (VTE), such as deep vein thrombosis (DVT) or pulmonary embolism (PE).
Edited by: Dr. Ben Appleby and Dr. Thomas Burnell
Reviewed by: Dr. Marcus Judge
Quiz
- 9121


